TABLE OF CONTENT
1 REPORT PROLOGUE
2 MARKET INTRODUCTION
2.1 DEFINITION 15
2.2 SCOPE OF THE STUDY 15
2.2.1 RESEARCH OBJECTIVE 15
2.2.2 ASSUMPTIONS 15
2.2.3 LIMITATIONS 16
3 RESEARCH METHODOLOGY
3.1 PRIMARY RESEARCH METHODOLOGY 18
3.2 SECONDARY RESEARCH METHODOLOGY 19
3.3 MARKET SIZE ESTIMATION 20
3.4 MARKET SHARE ANALYSIS 22
3.5 TRADE ANALYSIS 22
3.6 MARKET PRICING APPROACH 22
4 MARKET DYNAMICS
4.1 INTRODUCTION 23
4.2 DRIVER 24
4.2.1 GROWING DEMAND OF EMBOLIZATION PARTICLES FOR INTERVENTIONAL RADIOLOGY AND INTERVENTIONAL CARDIOVASCULAR PROCEDURE (IMPACT WEIGHTAGE- 35%) 24
4.2.2 EMBOLIZATION IS BEST MINIMALLY INVASIVE ALTERNATIVES AVAILABLE FOR THE
INTERVENTIONAL PROCEDURES (IMPACT WEIGHTAGE- 30%) 25
4.2.3 INCREASING PREVALENCE OF VARIOUS TYPES OF CANCER IS ONE OF THE MAJOR FACTOR RESPONSIBLE FOR MARKET GROWTH (IMPACT WEIGHTAGE- 25%) 26
4.2.4 FAVOURABLE REIMBURSEMENT SCENARIO (IMPACT WEIGHTAGE- 10%) 27
4.3 RESTRAINTS 28
4.3.1 LESS NUMBER OF INTERVENTIONAL NEURORADIOLOGISTS AND INTERVENTIONAL
NEURORADIOLOGY (INR) LABS (IMPACT WEIGHTAGE- 40%) 28
4.3.2 STRICT REGULATORY RULES (IMPACT WEIGHTAGE-60% 29
4.4 OPPORTUNITIES 30
4.4.1 RECENT ADVANCES IN MICROSPHERE TECHNOLOGIES 30
4.5 MEGA TRENDS 30
4.6 MACROECONOMIC INDICATORS 31
5 MARKET FACTOR ANALYSIS
5.1 PORTER’S 5 FORCES ANALYSIS 32
5.1.1 BARGAINING POWER OF SUPPLIERS 33
5.1.2 BARGAINING POWER OF BUYERS 33
5.1.3 THREAT OF NEW ENTRANTS 33
5.1.4 THREAT OF SUBSTITUTES 33
5.1.5 INTENSITY OF RIVALRY 33
5.2 VALUE CHAIN ANALYSIS 34
5.2.1 R&D 34
5.2.2 CLINICAL TEST & LEGAL ISSUES 35
5.2.3 MANUFACTURING 35
5.2.4 MARKETING & SALES 35
5.3 PURCHASING ACTIVITIES, STRATEGIES AND IMPLICATIONS 36
5.4 INVESTMENT OPPORTUNITY ANALYSIS 36
5.5 PRICING IMPACT OF EMBOLIZATION PARTICLE (LIPIODOL): EFFECTS & IMPLICATIONS 37
5.6 REIMBURSEMENT ISSUES IN EMBOLIZATION PROCEDURES 38
6 GLOBAL EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE
6.1 INTRODUCTION 40
6.2 RADIOEMBOLIZATION SPHERES 41
6.3 DRUG ELUTING BEADS 42
7 GLOBAL EMBOLIZATION PARTICLE MARKET, BY APPLICATION
7.1 INTRODUCTION 43
7.2 ONCOLOGY 45
7.3 UROLOGY 46
7.4 PERIPHERAL VASCULAR DISEASE 47
7.5 NEUROLOGY 48
8 GLOBAL EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION
8.1 INTRODUCTION 49
8.1.1 PROXIMAL 50
8.1.2 DISTAL 50
9 GLOBAL EMBOLIZATION PARTICLE MARKET, BY END USER
9.1 INTRODUCTION 51
9.2 HOSPITALS & CLINICS 52
9.3 AMBULATORY CENTERS 53
10 GLOBAL EMBOLIZATION PARTICLE MARKET, BY REGION
10.1 INTRODUCTION 54
10.2 AMERICAS 56
10.2.1 U.S. 59
10.2.2 CANADA 61
10.2.3 SOUTH AMERICA 63
10.3 EUROPE 66
10.3.1 GERMANY 69
10.3.2 FRANCE 71
10.3.3 UK 73
10.3.4 ITALY 75
10.3.5 SPAIN 77
10.3.6 REST OF EUROPE 79
10.4 ASIA PACIFIC 82
10.4.1 JAPAN 85
10.4.2 CHINA 87
10.4.3 INDIA 89
10.4.4 REPUBLIC OF KOREA 91
10.4.5 AUSTRALIA 93
10.4.6 REST OF ASIA PACIFIC 95
10.4.7 MIDDLE EAST & AFRICA 97
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION 100
11.2 COMPANY SHARE ANALYSIS 101
12 COMPANY PROFILES
12.1 BOSTON SCIENTIFIC CORPORATION 102
12.1.1 COMPANY OVERVIEW 102
12.1.2 FINANCIALS 102
12.1.3 PRODUCTS 102
12.1.4 STRATEGY 102
12.1.5 KEY DEVELOPMENTS 102
12.2 GUERBET 103
12.2.1 COMPANY OVERVIEW 103
12.2.2 FINANCIALS 103
12.2.3 PRODUCTS 103
12.2.4 STRATEGY 103
12.2.5 KEY DEVELOPMENTS 103
12.3 BTG INTERNATIONAL LTD 104
12.3.1 COMPANY OVERVIEW 104
12.3.2 FINANCIALS 104
12.3.3 PRODUCTS 104
12.3.4 STRATEGY 104
12.3.5 KEY DEVELOPMENTS 104
12.4 MEDTRONICS 105
12.4.1 COMPANY OVERVIEW 105
12.4.2 FINANCIALS 105
12.4.3 PRODUCTS 105
12.4.4 STRATEGY 105
12.4.5 KEY DEVELOPMENTS 105
12.5 SIRTEX 106
12.5.1 COMPANY OVERVIEW 106
12.5.2 FINANCIALS 106
12.5.3 PRODUCTS 106
12.5.4 STRATEGY 106
12.5.5 KEY DEVELOPMENTS 106
12.6 TERUMO 107
12.6.1 COMPANY OVERVIEW 107
12.6.2 FINANCIALS 107
12.6.3 PRODUCTS 107
12.6.4 STRATEGY 107
12.6.5 KEY DEVELOPMENTS 107
12.7 MERIT MEDICAL 108
12.7.1 COMPANY OVERVIEW 108
12.7.2 FINANCIALS 108
12.7.3 PRODUCTS 108
12.7.4 STRATEGY 108
12.7.5 KEY DEVELOPMENTS 108
13 MRFR CONCLUSION
13.1 KEY FINDINGS 109
13.1.1 FROM CEO’S VIEW POINT 109
13.1.2 UNMET NEEDS 109
13.2 KEY COMPANIES TO WATCH 109
14 APPENDIX
14.1 DISCUSSION BLUE PRINT 110
14.2 REFERENCES 112
TABLE 1 PRIMARY INTERVIEWS 18
TABLE 2 SAMPLE SIZE DETERMINATION OF END-USERS (HOSPITALS, CLINICS) 19
TABLE 3 AVERAGE PRICING OF LIPIODOL IN VARIOUS COUNTRIES (USD) 38
TABLE 4 GLOBAL EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION) 40
TABLE 5 GLOBAL EMBOLIZATION PARTICLE MARKET FOR RADIOEMBOLIZATION SPHERES, BY REGION,
2020-2027 (USD MILLION) 41
TABLE 6 GLOBAL EMBOLIZATION PARTICLE MARKET FOR DRUG ELUTING BEADS, BY REGION,
2020-2027 (USD MILLION) 42
TABLE 7 GLOBAL EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 43
TABLE 8 GLOBAL EMBOLIZATION PARTICLE MARKET FOR ONCOLOGY, BY REGION, 2020-2027 (USD MILLION) 45
TABLE 9 GLOBAL EMBOLIZATION PARTICLE MARKET FOR UROLOGY, BY REGION, 2020-2027 (USD MILLION) 46
TABLE 10 GLOBAL EMBOLIZATION PARTICLE MARKET FOR PERIPHERAL VASCULAR DISEASE, BY REGION,
2020-2027 (USD MILLION) 47
TABLE 11 GLOBAL EMBOLIZATION PARTICLE MARKET FOR NEUROLOGY, BY REGION, 2020-2027 (USD MILLION) 48
TABLE 12 GLOBAL EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION, 2020-2027 (USD MILLION) 49
TABLE 13 GLOBAL EMBOLIZATION PARTICLE MARKET FOR PROXIMAL, BY REGION, 2020-2027 (USD MILLION) 50
TABLE 14 GLOBAL EMBOLIZATION PARTICLE MARKET FOR DISTAL, BY REGION, 2020-2027 (USD MILLION) 50
TABLE 15 GLOBAL EMBOLIZATION PARTICLE MARKET, BY END USER, 2020-2027 (USD MILLION) 51
TABLE 16 GLOBAL EMBOLIZATION PARTICLE MARKET FOR HOSPITALS & CLINICS, BY REGION,
2020-2027 (USD MILLION) 52
TABLE 17 GLOBAL EMBOLIZATION PARTICLE MARKET FOR AMBULATORY CENTERS, BY REGION,
2020-2027 (USD MILLION) 53
TABLE 18 GLOBAL EMBOLIZATION PARTICLE MARKET, BY REGION, 2020-2027 (USD MILLION) 54
TABLE 19 AMERICAS EMBOLIZATION PARTICLE MARKET, BY COUNTRY, 2020 & 2027 (USD MILLION) 56
TABLE 20 AMERICA EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION) 57
TABLE 21 AMERICA EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 58
TABLE 22 AMERICA EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION, 2020-2027 (USD MILLION) 58
TABLE 23 AMERICA EMBOLIZATION PARTICLE MARKET, BY END USER, 2020-2027 (USD MILLION) 59
TABLE 24 U.S. EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION) 59
TABLE 25 U.S. EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 60
TABLE 26 U.S. EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION, 2020-2027 (USD MILLION) 60
TABLE 27 U.S. EMBOLIZATION PARTICLE MARKET, BY END USER, 2020-2027 (USD MILLION) 61
TABLE 28 CANADA EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION) 61
TABLE 29 CANADA EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 62
TABLE 30 CANADA EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION, 2020-2027 (USD MILLION) 62
TABLE 31 CANADA EMBOLIZATION PARTICLE MARKET, BY END USER, 2020-2027 (USD MILLION) 63
TABLE 32 SOUTH AMERICA EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION) 63
TABLE 33 SOUTH AMERICA EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 64
TABLE 34 SOUTH AMERICA EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION,
2020-2027 (USD MILLION) 64
TABLE 35 SOUTH AMERICA EMBOLIZATION PARTICLE MARKET, BY END USER, 2020-2027 (USD MILLION) 65
TABLE 36 EUROPE EMBOLIZATION PARTICLE MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 66
TABLE 37 EUROPE EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION) 67
TABLE 38 EUROPE EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 68
TABLE 39 EUROPE EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION, 2020-2027 (USD MILLION) 68
TABLE 40 EUROPE EMBOLIZATION PARTICLE MARKET, BY END USER, 2020-2027 (USD MILLION) 69
TABLE 41 GERMANY EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION) 69
TABLE 42 GERMANY EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 70
TABLE 43 GERMANY EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION, 2020-2027 (USD MILLION) 70
TABLE 44 GERMANY EMBOLIZATION PARTICLE MARKET, BY END USER, 2020-2027 (USD MILLION) 71
TABLE 45 FRANCE EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION) 71
TABLE 46 FRANCE EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 72
TABLE 47 FRANCE EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION, 2020-2027 (USD MILLION) 72
TABLE 48 FRANCE EMBOLIZATION PARTICLE MARKET, BY END USER, 2020-2027 (USD MILLION) 73
TABLE 49 UK EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION) 73
TABLE 50 UK EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 74
TABLE 51 UK EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION, 2020-2027 (USD MILLION) 74
TABLE 52 UK EMBOLIZATION PARTICLE MARKET, BY END USER, 2020-2027 (USD MILLION) 75
TABLE 53 ITALY EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION) 75
TABLE 54 ITALY EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 76
TABLE 55 ITALY EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION, 2020-2027 (USD MILLION) 76
TABLE 56 ITALY EMBOLIZATION PARTICLE MARKET, BY END USER, 2020-2027 (USD MILLION) 77
TABLE 57 SPAIN EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION) 77
TABLE 58 SPAIN EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 78
TABLE 59 SPAIN EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION, 2020-2027 (USD MILLION) 78
TABLE 60 SPAIN EMBOLIZATION PARTICLE MARKET, BY END USER, 2020-2027 (USD MILLION) 79
TABLE 61 REST OF EUROPE EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION) 79
TABLE 62 REST OF EUROPE EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 80
TABLE 63 REST OF EUROPE EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION,
2020-2027 (USD MILLION) 80
TABLE 64 REST OF EUROPE EMBOLIZATION PARTICLE MARKET, BY END USER, 2020-2027 (USD MILLION) 81
TABLE 65 ASIA PACIFIC EMBOLIZATION PARTICLE MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 82
TABLE 66 ASIA PACIFIC EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION) 83
TABLE 67 ASIA PACIFIC EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 84
TABLE 68 ASIA PACIFIC EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION, 2020-2027 (USD MILLION) 84
TABLE 69 ASIA PACIFIC EMBOLIZATION PARTICLE MARKET, BY END USER, 2020-2027 (USD MILLION) 85
TABLE 70 JAPAN EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION) 85
TABLE 71 JAPAN EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 86
TABLE 72 JAPAN EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION, 2020-2027 (USD MILLION) 86
TABLE 73 JAPAN EMBOLIZATION PARTICLE MARKET, BY END USER, 2020-2027 (USD MILLION) 87
TABLE 74 CHINA EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION) 87
TABLE 75 CHINA EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 88
TABLE 76 CHINA EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION, 2020-2027 (USD MILLION) 88
TABLE 77 CHINA EMBOLIZATION PARTICLE MARKET, BY END USER, 2020-2027 (USD MILLION) 89
TABLE 78 INDIA EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION) 89
TABLE 79 INDIA EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 90
TABLE 80 INDIA EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION, 2020-2027 (USD MILLION) 90
TABLE 81 INDIA EMBOLIZATION PARTICLE MARKET, BY END USER, 2020-2027 (USD MILLION) 91
TABLE 82 REPUBLIC OF KOREA EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION) 91
TABLE 83 REPUBLIC OF KOREA EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 92
TABLE 84 REPUBLIC OF KOREA EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION,
2020-2027 (USD MILLION) 92
TABLE 85 REPUBLIC OF KOREA EMBOLIZATION PARTICLE MARKET, BY END USER, 2020-2027 (USD MILLION) 93
TABLE 86 AUSTRALIA EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION) 93
TABLE 87 AUSTRALIA EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 94
TABLE 88 AUSTRALIA EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION, 2020-2027 (USD MILLION) 94
TABLE 89 AUSTRALIA EMBOLIZATION PARTICLE MARKET, BY END USER, 2020-2027 (USD MILLION) 95
TABLE 90 REST OF ASIA PACIFIC EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION) 95
TABLE 91 REST OF ASIA PACIFIC EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 96
TABLE 92 REST OF ASIA PACIFIC EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION,
2020-2027 (USD MILLION) 96
TABLE 93 REST OF ASIA PACIFIC EMBOLIZATION PARTICLE MARKET, BY END USER, 2020-2027 (USD MILLION) 97
TABLE 94 MIDDLE EAST & AFRICA EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE,
2020-2027 (USD MILLION) 97
TABLE 95 MIDDLE EAST & AFRICA EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 98
TABLE 96 MIDDLE EAST & AFRICA EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION,
2020-2027 (USD MILLION) 98
TABLE 97 MIDDLE EAST & AFRICA EMBOLIZATION PARTICLE MARKET, BY END USER, 2020-2027 (USD MILLION) 99
| ※参考情報 塞栓粒子（Embolization Particle）は、主に血管への血流を遮断するために使用される微小な粒子のことを指します。医療分野、特に放射線治療や介入放射線学において重要な役割を果たしています。塞栓粒子は、主に癌治療や異常血管の治療、肝疾患などの疾患に使用されることが多いです。これらの粒子は、肝臓がんや動静脈奇形、子宮筋腫などに対する治療の一環として用いられます。治療の目的は、腫瘍への血流を遮断することにより、その成長を抑制したり、症状を軽減することです。 塞栓粒子の種類は多岐にわたりますが、主に以下のようなものがあります。まず、ポリビニルアルコール（PVA）粒子は、非常に精密にコントロールされたサイズを持ち、血管内での塞栓効果が高いことから多くの場面で使用されます。次に、コラーゲンやゼラチン製の塞栓粒子があり、これらは生体適合性があり、自然に体内で分解される性質を持っています。また、メタルの塞栓粒子も存在し、主に特定の手技において使用されることがあります。これには、特に高い塞栓効果を求められる場合や、長期間にわたる効果が期待される場合があります。 塞栓粒子の用途は多岐にわたりますが、主なものとしては、腫瘍の血流遮断があります。特に肝臓がんに対する治療方法として、肝動脈塞栓療法があげられます。この療法では、肝動脈に塞栓粒子を注入することで、腫瘍への栄養供給を遮断します。これにより、腫瘍の成長を抑制したり、痛みや出血のリスクを軽減することが可能です。また、子宮筋腫に対しても、子宮動脈を塞栓することで筋腫のサイズを小さくすることが可能です。さらに、異常血管を治療する際にも使われ、動静脈奇形の塞栓処置などで非常に効果的です。 関連技術としては、画像診断技術が非常に重要です。CTやMRI、超音波検査などを用いて、塞栓を施すべき部位を正確に特定します。また、デジタル血管造影（DSA）などを使用して、血管の状態を詳細に観察し、塞栓治療の効果を確認することができます。これにより、治療の精度を向上させ、合併症のリスクを最低限に抑えることが可能です。 さらに、最近ではナノテクノロジーの進展により、より小型化された塞栓粒子が開発されています。これにより、さらなる血管内治療の精度向上が期待されています。ナノ粒子を用いることで、より標的に対する効果が高まるとともに、副作用の軽減が図れる可能性があります。また、放射性同位元素を用いた塞栓粒子も存在し、腫瘍に対する放射線治療を併用することができます。 塞栓粒子の使用においては、適切な粒子の選択と投与方法が非常に重要です。粒子のサイズや材質、投与量などを慎重に選ぶ必要があります。適切に使用されることで、塞栓粒子は多くの疾患に対して非常に有効な治療手段となります。ただし、使用には注意が必要で、合併症や副作用が起こる可能性もあるため、専門医による適切な判断が求められます。 これらの情報を総合すると、塞栓粒子は非常に重要な医療資材であり、血管内治療の分野での利用が期待されています。今後も研究や技術の発展により、より安全で効果的な治療法が開発され、さらに多くの患者に恩恵をもたらすことができるでしょう。 |
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
